Malocide

Pyrimethamine, the active ingredient in Malocide, is an antiprotozoal presented as an oral dosage form for systemic use. It is employed in the treatment and prevention of malaria and in the management of toxoplasmosis infections.

GNH USA supplies Malocide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malocide is an antiprotozoal agent used to address parasitic infections affecting the blood and tissues.

- Malaria: provides curative therapy and prophylactic protection against Plasmodium infection. - Toxoplasmosis: contributes to parasite clearance and reduces disease severity in acute and chronic infection.

Adverse reactions may occur with pyrimethamine therapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Rash: mild skin erythema or pruritus. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Bone marrow suppression: may cause anemia, leukopenia, or thrombocytopenia. - Severe skin reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis.

Before initiating therapy, consider the following safety measures.

- Renal function: assess kidney status and adjust monitoring in patients with impairment. - Hematologic monitoring: obtain baseline blood counts and repeat periodically. - Folate deficiency: supplement folic acid to reduce hematologic toxicity. - Pregnancy: risk unknown; avoid use unless benefits outweigh potential hazards. - Drug interactions: review concomitant medications for possible antagonism or additive toxicity. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Pyrimethamine may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Sulfonamides: antagonistic effect reducing antiprotozoal efficacy. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Methotrexate: additive bone‑marrow suppression, heightening hematologic toxicity.

Moderate Interactions (Monitor Closely): - Phenobarbital: may lower pyrimethamine plasma concentrations. - Phenytoin: can reduce drug levels, potentially compromising effectiveness. - Oral contraceptives: possible reduction in hormonal efficacy, consider alternative contraception.